• DOI:10.1200/JCO.2014.32.15_SUPPL.3017
Corpus ID: 79082193

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

@article{Chester2014BiomarkerCU,
  title={Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.},
  author={C. Chester and Serena Chang and J. Kurland and Idit Sagiv-Barfi and D. Czerwinski and Amanda Rajapaksa and E. Waller and Mohith Sadaram and Lori Richards and L. Cohen and C. M. Ahlers and M. Jure-Kunkel and H. Maecker and R. Levy and H. Kohrt},
  journal={Journal of Clinical Oncology},
  year={2014},
  volume={32},
  pages={3017-3017}
}

C. Chester, Serena Chang, +12 authors H. Kohrt

Published 2014

Medicine

Journal of Clinical Oncology

3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al., 2008) to increase peripheral activated CD8 T cells and IFN-inducible genes, thereby facilitating a cytolytic, antitumor, Th1 response. A multiparametric immune pharmacodynamic assessment of the effects of anti-CD137 therapy has not been previously performed. Methods: We employed the novel technology of mass cytometry time of flight (CyTOF) to investigate the patient… CONTINUE READING

View via Publisher

Save to Library

Create Alert

Cite

Launch Research Feed